Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMP27
- Development stage
- Preclinical
- Lead developer
- IMPACT Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IMP27 is a proteolysis-targeting chimera (PROTAC) designed to induce the targeted degradation of KAT6A (Lysine Acetyltransferase 6A). Developed by Impact Therapeutics, it is currently in preclinical development for the treatment of advanced solid tumors. KAT6A is an epigenetic regulator that plays a significant role in gene expression and is frequently dysregulated in various cancers. By recruiting an E3 ubiquitin ligase to KAT6A, IMP27 facilitates the ubiquitination and subsequent proteasomal degradation of the target protein, offering a potential therapeutic advantage over traditional enzymatic inhibition by eliminating both the catalytic and non-catalytic functions of KAT6A.
- Other names
- IMP27IMP-27IMP 27
02
Targets
KAT6A (Lysine acetyltransferase 6A)
Beyond the preview
Go deeper on IMP27.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMP27.